 
 
 
 
       1
   
 
 
  
  
Protecting with ARNI Against Cardiac Consequences of Coronavirus Disease 2019 
(PARACOR -19) 
 
 
 
[STUDY_ID_REMOVED]  
  
  
 
 
 
 
Compiled by:  
Duke University Medical Center  
Version 2 .0 Date: 2/26/2023  
 
 
  
 
  
Distributed by:  
 
 
G. Michael Felker, MD  Stephen J. Greene, MD  
Duke Clinical Research Institute  Duke Clinical Research Institute  
Duke University  Duke University  
200 Morris Street  200 Morris Street  
Durham, NC 27701  Durham, NC 27701  
 
 
 
 
 
       2
   
 
 
 Study Funding:    Novartis Pharmaceuticals  
 
Princip al Investigator s:   Stephen J. Greene, MD  
G. Michael Felker , MD  MHS  
          
 
Protocol Development Team:   Stephen J. Greene, MD  
G. Michael Felker , MD  MHS  
       Javed Butler, MD MPH MBA  
       Raymond J. Kim, MD  
  
   
  
 
   
 
 
 
 
 
 
       3
   
 
 
 1 LIST OF ABBREVIATIONS  
Abbreviation  Definition  
ACEI  Angiotensin -Converting Enzyme Inhibitor  
AE Adverse Event  
ARB Angiotensin Receptor Blocker  
ARNI  Angiotensin Receptor Neprilysin Inhibitor  
CRF Case Report Form  
DSMB  Data Safety Monitoring Board  
EF Ejection Fraction  
eGFR  Estimated Glomerular Filtration Rate  
GFR  Glomerular Filtration Rate  
HF Heart Failure  
HFpEF  Heart Failure with Preserved Ejection Fraction  
HFrEF  Heart Failure with Reduced Ejection Fraction  
ITT Intention To Treat  
IRB Institutional Review Board  
LV Left Ventricular  
LVAD  Left Ventricular Assist Device  
LVEF  
mmHG  
mmol/L  
MDRD  
NT-proBNP  Left Ventricular Ejection Fraction  
Millimeters  of mercury  
Millimole per liter  
Modification of Diet in Renal Disease  
N-terminal pro -B-type natriuretic peptide  
PO 
PPI 
SAE “Per os,” or by mouth  
Patient Package Insert  
Serious Adverse Event  
SBP Systolic Blood Pressure  
sST2  Soluble ST2  
  
  
 
 
 
 
       4
   
 
 
   
2 TABLE OF CONTENTS  
1 LIST OF ABBREVIATIONS  ................................................................................................ .....................  3 
2 TABLE OF CONTENTS ................................................................................................ ...........................  4 
3 EXECUTIVE SUMMARY ................................................................................................ ........................ 7  
4 OBJECTIVES  ................................................................................................................................ ......... 9  
4.1 Primary Objectives  ................................................................................................ ...................... 9  
4.2 Exploratory Objectives  ................................................................................................ ................ 9  
5 BACKGROUND AND STUDY RATIONALE  ................................................................ .............................. 9  
6 STUDY DESIGN  ..................................................................................................................................  10 
6.1 Screening and Randomization (Study Visit 1)  ............................................................................  10 
6.2 Dose Titration and Safety Visit  ..................................................................................................  11 
6.3 Final Study Visit  .........................................................................................................................  11 
7 PATIENT POPULATION  ...................................................................................................................... 11 
7.1 Study Population  .......................................................................................................................  11 
7.2 Inclusio n Criteria  .......................................................................................................................  11 
7.3 Exclusion Criteria  .......................................................................................................................  12 
8 TREATMENT  ......................................................................................................................................  12 
8.1 Intervention  .............................................................................................................................. 12 
8.2 Drug Dispensing  ........................................................................................................................ 13 
8.3 Drug Administration  .................................................................................................................. 13 
8.4 Drug Storage Requirements  ......................................................................................................  13 
8.5 Drug accountability ...................................................................................................................  13 
8.6 Destruction  ............................................................................................................................... 13 
8.7 Randomization,  Stratification and Blinding  ............................................................................... 13 
8.8
 Unblinding  ................................................................................................................................ . 14 
8.9 Concomitant Medication  ..........................................................................................................  14 
9 RECRUITMENT AND SCREENING PROCEDURES  .................................................................................  14 
9.1 Common Recruitment Procedures  ............................................................................................ 14 
 
 
 
 
       5
   
 
 
 9.2 Estimated Enrollment Period  ....................................................................................................  14 
9.3 Informed Consent  .....................................................................................................................  14 
9.4 Confidentiality and HIPAA Requirements .................................................................................. 15 
9.5 Protections of Human Subjects  ................................................................................................ . 15 
9.6 Summary of the Risks and Benefits  ...........................................................................................  15 
10 VISIT SCHEDULE AND ASSESSMENTS  ................................................................................................  16 
10.1 Baseline Evaluation, Enrollment and Randomization Visit  ........................................................ 16 
10.2 Follow- up Evaluations  ............................................................................................................... 17 
11 OUTCOME DETERMINATIONS  ........................................................................................................... 19 
11.1 Primary Endpoints  .....................................................................................................................  19 
11.2 Exploratory Endpoints  ............................................................................................................... 19 
12 PARTICIPANT SAFETY MONITORING AND REPORTING ......................................................................  19 
12.1 Institutional Review Boards  ......................................................................................................  19 
12.2 Adverse Event Definition ........................................................................................................... 20 
12.3 Suspected Adverse Reaction Definition .................................................................................... 20 
12.4 Serious Adverse Events (SAE)  ....................................................................................................  20 
12.5 Laboratory Test Abnormalities  ..................................................................................................  20 
12.6 Assessment of Causal Relationship  ...........................................................................................  20 
12.7 Assessment of Adverse Event Severity  ...................................................................................... 21 
12.8  Recording and Reporting of Adver se Events  ............................................................................  21 
12.9  Follow- up of Adverse Events  ....................................................................................................  21 
12.10   Expectedness  ...........................................................................................................................  22 
12.11   Suspect ed Unexpected Serious Adverse Reaction  ................................................................... 22 
12.12   Pregnancy ................................................................................................................................ . 22 
13 STATISTICAL METHODS AND DATA ANALYSIS  ...................................................................................  22 
13.1 General Design Issues  ............................................................................................................... 22 
13.2
 Sample Size Justification and Randomization  ........................................................................... 23 
13.3 Interim Analyses and Safety Reviews  ........................................................................................ 23 
13.4 Analysis of the Co- Primary Endpoints  .......................................................................................  23 
13.5 Analysis of Exploratory Endpoints  .............................................................................................  24 
 
 
 
 
       6
   
 
 
 14 DATA MANAGEMENT PROCEDURES  ................................................................................................ . 24 
14.1 Overview of Data Management  ................................................................................................  24 
14.2 Data Security  .............................................................................................................................  24 
14.3 Publication Policy  ...................................................................................................................... 24 
15 STUDY ADMINISTRATION  .................................................................................................................. 24 
15.1 Data and Safety Monitoring Board  ............................................................................................ 24 
15.2 Biomarker Core Laboratory  ....................................................................................................... 25 
16 REGULATORY ISSUES  .........................................................................................................................  25 
16.1 Ethics and Good Clinical Practice  ..............................................................................................  25 
16.2 Institutional Review Board/Independent Ethics Committee  .....................................................  25 
16.3 Informed Consent  .....................................................................................................................  25 
17 APPENDICES  ......................................................................................................................................  26 
17.1 Appendix A - Schedule of Assessments  .....................................................................................  26 
18 REFERENCES  ......................................................................................................................................  27 
 
 
 
 
 
       7
   
 
 
 3 EXECUTIVE SUMMARY  
 
Title Protecting with ARNI Against Cardiac Consequences of Coronavirus 
Disease 2019 (PARACOR -19) 
Indication To decrease  risk of cardiac injury and abnormalities in cardiac structure 
and function following COVID -19 infection 
Location Duke University Hospital   
Brief Rationale  
 Although many patients presenting with Coronavirus Disease 2019 
(COVID -19) face high- risk of death, the vast majority of patients recover 
from the acute infection, either in the hospital or at home. Nonetheless, 
despite clinical improvement or resolution of symptoms, accumulating 
evidence supports significant potential for longer -term and insidious 
cardiac involvement. Moreover, within the heart, the virus appears to  
localize to interstitial cells and the extracellular matrix, with relative 
sparing of the myocytes themselves. These data, combined with others 
noting high levels of inflammation with COVID -19, suggest that the virus 
may increase propensity for downstream cardiac fibrosis and dysfunction. These collective data raise significant concerns that 
cardiomyopathy , heart failure, or other cardiovascular complications  will 
evolve as the natural history of COVID -19 for many patients who recover 
from acute infection.  
 Pre-clinical and clinical data across multiple cardiometabolic conditions 
suggest that sacubitril/valsartan may be particularly well -suited to prevent 
adverse cardiac remodeling and new -onset HF following COVID -19 
infection. Renin- angiotensin- aldosterone system (RAAS) inhibition has 
been postulated to have a cardio- protective role in COVID -19, but there 
is biologic plausibility that a dual compound with a neprilysin inhibitor 
would better prevent cardiac injury and dysfunction. In this context, the 
goal of the PARACOR -19 trial is to generate further evidence regarding 
the effects of sacubitril/valsartan on markers of cardiac injury, structure, 
and function among patients who have recovered from acute COVID -19 
infection.  
 Hypothesis:  Among  patients with cardiovascular risk factors and  4-16 
weeks from prior COVID -19 infection, sacubi tril/valsartan  will reduce 
levels of high- sensitivity troponin T and/or soluble ST2 (sST2), compared 
with placebo.  
Study Design  The PARACOR -19 trial will be an investigator -initiat ed, single center, 
double- blind trial of patients who have recovered from acute COVID -19 
 
 
 
 
       8
   
 
 
 infection. There will be 1:1 randomization to sacubitril/valsartan or 
placebo. Approximately 50 participants  will be randomized into the study.  
A subset of approximately 30 patients will be enrolled in the cardiac 
magnetic resonance (CMR) sub- study.   
Treatment  Sacubitril/valsartan versus placebo  
Primary Objective  
and Endpoint  1. Change from baseline in high -sensitivity troponin T 
2. Change from baseline in sST2  
Exploratory  
Objectives and Endpoints 1. Change from baseline in high -sensitivity C -reactive peptide  
2. Change form baseline in PINP  
3. Change from baseline in Galectin-3 
4. Change from baseline in NT -proBNP  
5. Change from baseline in GDF -15 
6. Change from baseline in IL-6 
7. Change from baseline in CITP  
8.     Change from baseline in CMR measures (LVEF,  LVEDVi, LVESVi, 
Native T1, Native T2)  
9. Change from baseline in focal fibrosis by delayed- enhancement  
10. Change from baseline in focal fibrosis as percentage of LV 
myocardial mass  
11. Change from baseline in health related quality of life, as measured 
by EQ -5D utility score and EQ -5D visual analog scale 
  
 
 
 
 
       9
   
 
 
 4 OBJECTIVES  
4.1 Primary Objectives 
To determine the effect of sacubitril/valsar tan versus placebo over 12 weeks on biomarkers of 
cardiac injury and fibrosis, as reflected in changes in high- sensitivity troponin T and sST2.  
 
Hypothesis:  Among  patients with cardiovascular risk factors and 4- 16 weeks from prior COVID -
19 infection, sacubtril/valsartan will reduce levels  of high- sensitivity troponin T and/or soluble 
ST2 (sST2), compared with placebo.  
4.2 Exploratory  Objectives 
To determine the effect of sacubitril/valsartan versus placebo over 12 weeks on cardiac 
biomarkers and measures of cardiac dysfunction and fibrosis  on cardiac magnetic resonance 
imaging, as reflected by the following exploratory  endpoints:.  
 1. Change from baseline in high- sensitivity C -reactive peptide  
2. Change form baseline in PINP  
3. Change from baseline in Galectin-3 
4. Change from baseline in NT -proBNP  
5. Change from baseline in GDF -15 
6. Change from baseline in IL-6 
7.     Change from baseline in CITP  
8. Change from baseline in cardiac MRI ( CMR ) measures (LVEF, LVEDVi, LVESVi, Native 
T1, Native T2)  
9. Change from baseline in focal fibrosis by delayed- enhancement  
10. Change from baseline in focal fibrosis as percentage of LV myocardial mass  
11. Change from baseline in health related quality of life, as measured by EQ -5D utility score 
and EQ -5D visual analog scale 
5 BACKGROUND AND STUDY RATIONALE  
Although many patients presenting with Coronavirus Disease 2019 (COVID -19) face high- risk of 
death, the vast majority of patients recover from the acute infection, either in the hospital or at 
home. Nonetheless, despite clinical improvement or resolution of symptoms, accumulating evidence supports significant potential for longer -term and insidious cardiac involvement. For 
example, in a recent study of patients seen a mean 71 days after COVID -19 diagnosis, 76% 
had detectable high- sensitivity troponin, 78% had demonstrable cardiac involvement on cardiac 
magnetic resonance (CMR) imaging, and 60% had evidence of cardiac inflammation by abnormal T1 and T2 imaging.
1 Two-thirds of these patients recovered at home and there were 
no meaningful differences in troponin or CMR measures between patients who did and did not 
require hospitalization, suggesting that ongoing cardiac involvement may be common even 
 
 
 
 
       10
   
 
 
 among those with a mild acute presentation.1 Likewise, in an autopsy study of patients with 
COVID -19 pneumonia as the clinical cause of death, 62% of patients had virus present in the 
heart, despite not meeting clinical or histologic criteria for acute myocardit is.2 Viral load was high 
and evidence of active viral replication was seen in most cases.2 Notably , the virus appeared to 
localize to interstitial cells and the extracellular matrix of the heart, with relative sparing of the 
myocytes themselves.3 These data, combined with others noting high levels of inflammation 
with COVID -19, suggest that the virus may increase propensity for downstream cardiac fibrosis 
and dysfunction. These collective data raise significant concerns that cardiomyopathy and heart failure will evolve as the natural history of COVID -19 for many patients who recover from acute 
infection.
4  
Pre-clinical and clinical data across multiple cardiometabolic conditions suggest that 
sacubitril/valsartan may be particularly well -suited to prevent adverse cardiac remodeling and 
new-onset HF following COVID -19 infection. Renin- angiotensin- aldosterone system (RAAS) 
inhibition has been postulated to have a cardio- protective role in COVID -19, but there is strong 
biologic plausibility that a dual compound with a neprilysin inhibitor would better prevent cardiac injury and dysfunction.
5 Across cardio- renal disease states, compared with ACEI/ARB therapy, 
sacubitril/valsartan offers superior cardio- protection for reducing clinical events and biomarkers 
of cardiac injury/ wall stress (e.g., troponin, natriuretic peptides), and these incremental benefits 
emerge quickly within a few weeks.6-11 Likewise, compared with ACEI/ARB, sacubitril/valsartan 
lowers levels of pro- inflammatory cytokines and other inflammatory biomarkers.12-14 Most 
recently, among patients with preserved ejection fraction, sacubitril/valsartan was shown to 
favorably alter biomarkers of cardiac extracellular matrix and collagen regulation compared with 
valsartan, adding further support for an anti -fibrotic mechanism well -suited to combat the 
propensity of COVID -19 for the cardiac inter stitium.15  
In this context, the goal of the PARACOR -19 trial is to generate further evidence regarding the 
effects of sacubitril/valsartan on markers of cardiac injury, structure, and function among 
patients who have recovered from acute COVID -19 infection.  
 
6 STUDY DESIGN  
6.1 Screening and Randomization ( Study Visit 1)  
Willing participants deemed likel y to me et eligibility criteria will be consented. Participants  will 
have an initial screening evaluation, including laboratory tests , at which time preliminary subject  
eligibility will be confirmed. Patients will also complete EuroQOL- 5D (EQ -5D) surveys  in order to 
be eligible . Participants consenting for and meeting entry criteria for the CMR substudy will 
undergo a CMR examination.  
 
Patients confirmed to meet study eligibility criteria will be randomized 1:1  in double- blind fashion 
to sacubitril/valsartan twice daily versus matching placebo twice daily. The starting dose of 
study drug will be dictated by systolic blood pressure. If systolic blood pressure is 100-120 
mmHg at randomization, participants will receive sacubitril/valsartan 24/26 mg twice daily or 
 
 
 
 
       11
   
 
 
 matching placebo. If systolic blood pressure >120 mmHg at randomization, participants will 
receive sacubitril/valsartan 49/51 mg twice daily  or matching placebo.  At time of randomization, 
patients will also have serum biomarkers collected for central and local laboratory analysis.  
6.2 Dose Titration and Safety Visit   
Patients will return between 7 and 21 days post-randomization for Study  Visit 2 . At this visit, 
tolerability and adherence to study medication will be assessed , renal function and potassium 
levels will be checked via local labs, and patients will have the dose of medication titrated based 
on systolic blood pressure and clinician assessment regarding presence of symptomatic 
hypotension. 
 If systolic blood pressure >100 mmHg and no symptomatic hypotension or deemed medication-
related adverse effects, dose of study medication will be increased to the next highest dose of 
sacubitril/valsartan or matching placebo (i.e., patients originally receiving sacubitril/valsart an 
24/26 mg twice daily will be increased to sacubitril/valsartan 49/51 mg twice daily; patients 
originally receiving sacubitril/valsartan 49/51 mg twice daily will be increased to 
sacubitril/valsartan 97/103 mg twice daily) . Patients not meeting criteria for dose uptitration will 
remain on their original dose of study therapy, as tolerated. For patients who are reporting 
symptomatic hypotension or other possible medication related adverse effects from study drug, 
the investigator may use their discretion in decreasing the dose of study drug to the next lowest 
dosing level.    
6.3 Final Study Visit   
Participants will return for a final study visit between 77 and 91 days (11-13 weeks) for the 12-
week visit (Study Visit 3) . Tolerability and adherence to study medication will be assessed, and 
renal function and potassium levels will be checked via local labs. Participants will also have serum biomarkers collected for central and local laboratory analysis. Participants who 
consented for the CMR sub- study will undergo a CMR examination.  
7 PATIENT  POPULATI ON  
7.1 Study Population  
It is anticipated that approximately 5 0 participants  meeting eligibility criteria listed below will be 
randomized into the study.  It is anticipated that 30 of these patients will be included within the 
CMR substudy. Individuals  suitable for this protocol are patients with cardiovascular risk factors 
and 4- 16 weeks from prior COVID -19 infection. 
7.2 Inclusion Criteria  
1. Patient with a history of laboratory proven -diagnosis of COVID -19 who is 4- 16 weeks 
 
 
 
 
       12
   
 
 
 from their last positive COVID -19 test  
2. Systolic blood pressure ≥100 mmHg at screening  
3. ≥18 years of age  
4. Successful collection of baseline serum biomarkers  
5. Successful completion of baseline EQ -5D questionnaire  
6. Successful completion of baseline CMR study (CMR sub- study only)  
7. High-sensitivity troponin at or above the level of detection on screening labs  
8. Presence of ≥1 of the following:  
a. Age ≥60  
b. History of atherosclerotic cardiovascular disease (ASCVD), including myocardial 
infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or 
peripheral artery disease  
c. Diabetes mellitus (Type 1 or Type 2)  
d. Body mass index ≥35 kg/m2 
e. eGFR  30-60 ml/min/1.73m2 
f. History of atrial fibrillation/flutter 
7.3 Exclusion Criteria  
1. Fever within the past 96 hours of >100.3 degrees Fahrenheit  
2. Actively receiving therapy with an angiotensin- converting enzyme inhibitor (ACEI), 
angiotensin II receptor blocker (ARB), aliskiren, or sacubitril/valsartan  
3. Last known left ventricular ejection fraction of ≤40%  
4. eGFR <30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy  
5. Serum potassium >5.0 mEq/L on screening labs  
6. Prior intolerance, allergy  or angioedema to ACEI, ARB, or  sacubitril/valsartan  
7. Pregnant or breast -feeding  
8. In women of childbearing age, unwillingness to use birth control for the duration of the 
study  
9. History of heart transplant or durable left ventricular assist device  
10.   Currently implanted permanent pacemaker, defibrillator, or other device or condition 
that would preclude CMR testing (CMR sub- study only)  
11. Currently participating in another trial of an investigational medication or device for 
COVID-19.   
12. Any other condition that in the judgment of the investigator would jeopardize the 
patient’s compliance with the study protocol  
8 TREATMENT  
8.1 Intervention  
This will be a 2- arm randomized, double- blind, controlled trial . The therapeutic intervention will 
be treatment with either sacubitril/valsartan or placebo. Study drug will be given for 12 weeks 
 
 
 
 
       13
   
 
 
 (+/- 1 week) .   
8.2 Drug Dispensing  
Sacubitril/valsartan and matching placebo  will be provided to Duke University Hospital  by 
Novartis Pharmaceuticals . Participants will receive a sufficient supply of study drug at each 
study visit to last until the next study visit  by a blinded member of the study team . Drug storage, 
inventory, accountability, and dispensing will be managed at  Duke University Hospital . 
Participants  will be instructed to take the medication as required by the protocol and compliance 
will be assessed at each visit.  
8.3 Drug Administration  
Subjects will take sacubitril/valsartan or  placebo twice daily by mouth, wit h dosing determined 
as outlined in Section 6 above.   
8.4 Drug Storage Requirements  
Study mediation must be received by designated personnel at Duke University Hospital , 
handled and stored safely and properly, and kept in a secured location to which only the 
investigator and designated site personnel have access. Upon receipt, doses of 
sacubitril/valsartan and matching placebo s should be stored according to the instructi ons 
specified on the drug labels.  
8.5 Drug accountability  
Participants  are instructed to return all used, partly used and unused trial product at each study 
visit. Returned trial  product(s) (used, partly used or unused including empty packaging material) 
must be stored separately from the non-allocated trial product(s) until drug accountability has 
been reconciled. The investigator s will keep track of all received, used, partly used and unused 
trial product s. 
8.6 Destruction  
Used and unused study drug may be destroyed at the site according to accepted pharmacy 
practice, local and national guidelines, using the site’s destruction procedure.  8.7 Randomization, Stratification and Blinding  
Patients will be consented and enrolled at the first study visit.  Eligible patients will be 
randomized in a 1:1 allocation ratio to one of two  treatment groups. Since this is a single center 
pilot study, randomization will not involve a permuted block design or any stratification.  
 Blinding of the study, with respect to treatment groups, will be preserved by the use of matching placebo. The investigator may be asked at the end of the trial if they had obtained any 
 
 
 
 
       14
   
 
 
 information which may have led to the unbl inding of treatment.   
8.8 U nblinding  
The investigator will be given access to the treatment code for their participants for emergency 
unblinding only.  Any suspected study drug- related events should be treated as though the 
subject received sacubitril/valsartan.  Randomization data are kept strictly confidential, 
accessible only to authorized persons, until the time of unblinding. Randomization codes will be provided to Novartis Pharmaceuticals at the time of study initiation. Upon completion of the 
double blind period, Novartis Pharmaceuticals will unblind data in the Argus safety database 
once database lock is completed and confirmed by Duke University Medical Center. This time 
frame is in accordance with Novartis standard operating procedures and unblinding will take place in coordination with the Duke study.  
8.9 Concomitant Medication 
Participants  should be tr eated per standard care with their regular clinicians . However, the 
following medications should not be taken during the treatment period of this study: ACEI, ARB, 
aliskiren, or sacubitril/valsartan (other than blinded study drug), bile acid sequestering agents 
(e.g., cholestyramine), and nesiritide or intravenous nitrates (interrupt or discontinue study drug, 
as concomitant administration of sacubitril/valsartan with nesiritide or intravenous nitrates has not been studied).  
 The following medications should be used with caution during the study period: agents that raise potassium (e.g., potassium sparking diuretics, potassium supplements, mineralocorticoid receptor antagonists), and phosphodiesterase- 5 inhibitors (may increase risk of hypotension).  
9 RECRUITMENT AND SCREENING PROCEDURES  
9.1 Common Recruitment Procedures  
Individual  meeting eligibility criteria will be approached regarding participation in this study .  
9.2 Estimated Enrollment Period 
This study will randomize approximately 50 subject s in the Duke University Health System in the 
U.S. The anticipated enrollment period is approximately 12 months.  
9.3 Informed Consent  
Study personnel  will explain to eligible individuals  the purpose of the study, study interventions 
and evaluations, and the potential risks and benefits of participation, and will answer any questions. If a subject  agrees to participate  in the study , they will review and sign the Duke 
University  institutional review board ( IRB) approved informed consent form (ICF).  
 
 
 
 
       15
   
 
 
 9.4 Confidentiality and HIPAA Requirements 
All information collected on study subject s will be stored in a confidential manner using the 
procedures in place at Duke University Hospital . Only approved study personnel will have 
access to data collected as part of the s tudy. Consented s tudy subject s will be identified by a 
subject  ID number  on all study documents.  
9.5 P rotections of Human Subjects  
Protections for human subjects of research are required under Department of Health and 
Human Services (HHS) regulations at 21 CFR parts 50,  56, and 312. 
9.6 Summary of the Risks and Benefits  
Blood draws: The risks of  dr awing blood include bleeding at the puncture site, bruising and pain. 
These occur in a very small portion of the population.   
 
Cardiac Magnetic Resonance Imaging (sub- s tudy patients only):  Serious reactions to the 
contrast agent used during some MRI tests are very rare. However, side effects are possible 
and include headache, nausea, dizziness, changes in taste, and allergic reactions.  Rarely, the 
contrast agent can harm people who have severe kidney or liver disease. The substance may cause nephrogenic systemic fibrosis.  
 
Sacubitril/valsartan: S
 acubitril/valsartan is indicated to reduce the risk of cardiovascular death 
and hospitalization for heart failure in adult patients with chronic heart failure.7, 8, 16 Moreover, 
sacubitril/valsartan ha s been shown to reduce mortality in patients with heart failure and 
reduced ejection fraction (HFrEF).7 This agent is recommended in all patients with HF rEF (Class 
I, Level of Evidence B -R), unless contraindicated.17  
 
Sacubitril/v alsartan is teratogenic and contraindicated in pregnancy. Use of drugs that act on the 
renin- angiotensin system  (of which sacubitril/valsartan is included)  during the second and third 
trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, discontinue study drug as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third 
trimesters of pregnancy.  There is no information regarding the presence of sacubitril/valsartan 
in human milk, the effects on the breastfed infant, or the effects on milk production. Sexually active subjects must agree to use appropriate contraception as long as they are taking study drug.  Medically acceptable contraceptives include:  
 
 
 
 
 
       16
   
 
 
 • surgical sterilization (such as a tubal ligation or hysterectomy)  
• approved hormonal contraceptives (such as birth control pills, patches, implants or 
injections)  
• barrier methods (such as a condom or diaphragm) used with a spermicide, or  
• Intrauterine device (IUD)  
 
Sacubitril/valsartan should be used with caution in the setting of concomitant non- steroidal anti -
inflammatory drugs, lithium, other potassium -sparing diuretics. Sacubitril/valsartan is 
contraindicated with use an ACEI, ARB, and should not be used with aliskiren in patients with diabetes.   
 In the PARADIGM -HF trial of patients with chronic heart failure with reduced ejection fraction, 
sacubitril/valsartan reduced the risk of cardiovascular mortality or heart failure hospitalization by 
20%, as compared with guideline- indicated ACEI therapy (i.e., enalapril). In the PARADIGM -HF 
trial, use of sacubitril/valsartan was associated with a greater incidence of angioedema than the 
comparator drug enalapril (0.5% vs. 0.2%).
7 The risk of angioedema with sacubitril/valsartan 
compared with enalapril was relatively greater among Black patients (2.4% vs. 0.5%). Patients 
with a history of angioedema are contraindicated from taking this drug. Trial data indicate adverse reactions occurring ≥5% are hypotension, hyperkalemia, cough, dizziness, and renal 
failure. Symptomatic hypotension in PARADIGM -HF was more common among patients taking 
sacubitril/valsartan than enalapril (18% vs. 12%) .
7 In the PARAGON -HF trial, which tested the 
efficacy and safety of sacubitril/valsartan versus valsartan among patients with heart failure with 
preserved ejection fraction, no new adverse reactions were identified.8  
10 VISIT SCHEDULE AND ASSESSMENTS 
10.1 Baseline Evaluation , Enrollment  and Randomization Visit  
A schedule of assessments throughout the study is also provided in Appendix A. 
 
Study Visit 1 ( Enrollment  and Randomization) 
This visit will include the screening and informed consent process followed by a baseline assessment including:  
• Demographics and m edical history  
• Review of medications patient is actively taking, and the doses  
• Vital signs, including systolic and diastolic blood pressure, heart rate, height, weight  
• EQ-5D quality of life questionnaire  
• Residual COVID -19 symptoms  
• Local  laboratory testing, including the following:  
 Basic metabolic/renal function panel, including s odium , potassium , chloride , 
CO2/bicarbonate , blood Urea Nitrogen (BUN) , creatinine  
 High-sensitivity troponin  
 
 
 
 
       17
   
 
 
 • Central laboratory testing, including the following  
 High-sensitivity troponin T  
 sST2  
 hs-CRP  
 PINP  
 Galectin -3 
 NT-proBNP  
 GDF-15 
 IL-6  
 CITP  
• CMR examination, with intravenous gadolinium contrast  (CMR sub -study patients only)  
• Urine pregnancy test on women of childbearing potential  
 
Patients will be initiated on blinded study medication, as dictated by systolic blood pressure. If systolic blood pressure is 100-120 mmHg at randomization, participants will receive  
sacubitril/valsartan 24/26 mg twice daily or matching placebo. If systolic blood pressure >120 
mmHg at randomization, participants w ill receive  sacubitril/valsartan 49/51 mg twice daily or 
matching placebo.  
 
10.2 Follow -up Evaluations  
 
Study Visit 2 ( T
 itration Visit)  
Visit 2 should take place within 7- 21 days after the randomization visit .  
Assessments at this visit include:  
• Review of medications patient is actively taking, and the doses  
• Vital signs, including systolic and diastolic blood pressure, and heart rate  
• Local laboratory testing, including the following:  
 Basic metabolic/renal function panel, including s odium , potassium , chloride , 
CO2/bicarbonate , BUN, c reatinine 
• Urine pregnancy test on women of childbearing potential  
• Adverse event monitoring, including hospitalizations  
• Study medication adherence  
 
If systolic blood pressure >100 mmHg and no symptomatic hypotension or deemed medication-
related adverse effects, dose of study medication will be increased to the next highest dose of 
sacubitril/valsartan or matching placebo (i.e., patients originally receiving sacubitril/valsartan 24/26 mg twice daily will be increased to sacubitril/valsartan 49/51 mg twice daily; patients 
originally receiving sacubitril/valsartan 49/51 mg twice daily will be increased to 
sacubitril/valsartan 97/103 mg twice daily). Patients not meeting criteria for dose uptitration will 
remain on their  original dose of study therapy, as tolerated.  For patients who are reporting 
 
 
 
 
       18
   
 
 
 symptomatic hypotension or other possible medication related adverse effects from study drug, 
the investigator may use their discretion in decreasing the dose of study drug to the next lowest dosing level.    
  
Study Visit 3 ( F
 inal Study Visit ) 
Participants will return for a final study visit between 77 and 91 days (11- 13 weeks) for the 12-
week visit.  
Assessments at this visit include:  
• Review of medications patient is actively taking, and the doses  
• Vital signs, including systolic and diastolic blood pressure, heart rate, weight  
• EQ-5D quality of life questionnaire  
• Residual COVID -19 symptoms  
• Local laboratory testing, including the following:  
 Basic metabolic/renal function panel, i ncluding s odium , potassium , chloride , 
CO2/bicarbonate , BUN, c reatinine 
• Central laboratory testing, including the following  
 High-sensitivity troponin T  
 sST2  
 hs-CRP  
 PINP  
 Galectin -3 
 NT-proBNP  
 GDF-15 
 IL-6  
 CITP  
• CMR examination, with intravenous gadolinium contrast (CMR sub -study patients only)  
• Urine pregnancy test on women of childbearing potential  
• Adverse event monitoring, including hospitalizations   
• Study medication adherence  
 
Study Drug Interruption:  
If a subject should stop taking study medication for any reason before completing the 12 weeks 
of study drug dosing,  an attempt should be made to restart the study drug at the last tolerated 
dose when the subject is stable, per physician discretion.  If the  treating physician decides to 
stop study medication a nd start the patient on an ACEI, then a 36 hour wash- out period is 
required after the last dose of study  drug before starting the ACEI . All subjects will complete all 
study assessments through study visit 3, regardless of whether they continue to receive t he 
study drug for the full 12 weeks.  
 
Unscheduled Visits:  
If the Investigator determines that a participant should be brought to the clinic to be evaluated 
 
 
 
 
       19
   
 
 
 for a potential change in study drug dose between scheduled study visits, an “ unscheduled visit ” 
should be done. Study drug dose changes will be recorded in the eCRF.  
Assessments at this visit include:  
• Interim history  
• Review of medications patient is actively taking, and the doses  
• Vital signs, including systolic and diastolic blood pressure, and heart rate  
• Local laboratory testing, including the following:  
 Basic metabolic/renal function panel, including s odium , potassium , chloride , 
CO2/bicarbonate , BUN, c reatinine 
• Adverse event monitoring  
• Study medication adherence  
11 OUTCOME DETERMINATIONS  
11.1 Primary Endpoint s 
1. Relative change from baseline in high -sensitivity troponin T levels from randomization to 
12 weeks .  
2. Relative change from baseline in sST2  from randomization to 12 weeks.   
11.2 Exploratory  Endpoints  
1. Change from baseline in high -sensitivity C-reactive peptide  
2. Change form baseline in PINP  
3. Change from baseline in Galectin -3 
4. Change from baseline in NT- proBNP  
5. Change from baseline in GDF -15 
6. Change from baseline in IL -6 
7. Change from baseline in CITP  
8. Change from baseline in CMR measures (LVEF, LVEDVi , LVESVi, Native T1, Native T2)  
9. Change from baseline in focal fibrosis by delayed -enhancement  
10. Change from baseline in focal fibrosis as percentage of LV myocardial mass  
11. Change from baseline in health related quality of life, as measured by EQ -5D utility sc ore 
and EQ -5D visual analog scale 
12 PARTICIPANT SAFETY MONITORING AND REPORTING  
12.1 Institutional Review Boards  
The study protocol, consent form, and other study documents  will be submitted to Duke 
University  IRB for approval . Any amendments to the protocol, other than minor administrative 
changes, must be approved by each Duke University IRB before they are implemented.  
 
 
 
 
       20
   
 
 
 12.2 Adverse Event Definition  
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in 
a participant , whether or not considered drug or biologic related. An AE can therefore be any 
undesirable sign, symptom or medical condition occurring after starting study drug, even if the event is not considered to be related to the pharmaceutical product.  
12.3 Suspected Adverse Reaction Definition  
A suspected adverse reaction (SAR) is any adverse event for which there is a reasonable 
possibility that the drug caused the event. “Reasonable possibility” suggests there is a causal 
relationship between the drug and the adverse event. “Suspected adverse reaction” implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event  caused by a drug.  
12.4 Serious Adverse Events (SAE)  
An adverse event or suspected adverse reaction is considered serious if the investigator or sponsor believes any of the following outcomes occurred: 
• Death  
• Life-threatening AE:  Places the subject  at imm ediate risk of death at the time of the event 
as it occurred. It does not include an AE that, had it occurred in a more severe form, might have caused death.  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.  
• Inpatient hospitalization or prolongation of hospitalization.  
• Congenital anomaly or birth defect.  
• Important medical events that may not result in death, be life threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the participant  and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition above.  This 
determination is based on the opinion of the investi gator.  
12.5 Laboratory Test Abnormalities  
For laboratory test abnormalities that meet the definition of an SAE, that required the participant  
to have the investigational product discontinued or interrupted or require the participant  to 
receive specific cor rective therapy, the clinical diagnosis rather than the laboratory term will be 
used by the reporting investigator (e.g., anemia versus low hemoglobin value).  
12.6 Assessment of Causal Relationship  
A medically- qualified investigator must assess the relationship of any AE to the use of study 
drug, based on available information, using the following guidelines:  
 
 
 
 
       21
   
 
 
 • Not related: There is not a reasonable causal relationship to the investigational product 
and the adverse event.  
• Unlikely related:  No temporal association or the cause of the event has been identified, 
or the drug or biologic cannot be implicated.  
• Possibly related:  There is reasonable evidence to suggest a causal relationship between 
the drug and adverse event.  
• Related:  There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely.  
12.7 Assessment of Adverse Event Severity 
The determination of adverse event severity rests on medical judgment of a medically -qualified 
investigator. The severity of AEs will be graded using the following definitions:  
• Mild: Awareness of sign, symptom, or event, but easily tolerated;  
• Moderate: Discomfort enough to cause interference with usual activity and may warrant 
intervention;  
• Severe: Incapacitating with inability to do usual activities or significantly affects clinical 
status, and warrants intervention.  
12.8  Recording and Reporting of A dverse Events  
The site Investigator is responsible for monitoring the safety of subject s enrolled into the study.  
  
All AEs occurring from signed informed consent through study visit 3 will be captured on the AE 
eCRF. For patients who die during the course of the study,  the cause of death will be reported 
by the investigator in the eCRF . The Duke Heart  Center Clinical Research Unit will share all 
SAEs with Novartis Pharmaceuticals within 24 hours after the investigators are made aware. AE reports will be shared with Novartis Pharmaceuticals, as requested.   
Any misuse or  abuse of the study  drug, other medication errors and uses outside of what is 
foreseen in the protocol (irrespective of whether  a clinical event has occurred)  will also be 
documented in the eCRF.  
12.9  Follow -up of Adverse Events  
When additional relevant information becomes available, the investigator will record follow -up 
information according to the same process used for reporting the initial event as described 
above. The Investigator will follow all reportable events until resolution, stabilization or the event is otherwise explained.  
 Investigators are also responsible for promptly reporting AEs to Duke University IRB  in 
accordance with local requirements. The Data Safety Monitoring Board ( DSMB ) will review 
detailed safety data approximately every 6 months throughout the study.  
 
 
 
 
       22
   
 
 
 12.10   Expectedness  
The expectedness of an AE or Suspected Adverse Reaction ( SAR) shall be determined 
according to the most current patient package insert (PPI). Any AE that is not identified in 
nature, severity, or specificity in the current PPI is considered unexpected. Events that are 
mentioned in the PPI as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but not specifically mentioned as occurring with the 
particular drug under investigation are considered unexpected.  
12.11  S uspected Un expected Serious Adverse Reaction  
AEs that meet the criteria of serious, related to study drug, and unexpected per PPI , qualify for 
expedited reporting to the regulatory authorities. The site Investigator will assess all SAE’s 
occurring at his/her site and evaluate for “unexpectedness” and relationship to study drug. The 
site Investigator is required to complete and submit a voluntary  MedWatch Report for events 
viewed as serious, study drug related and unexpected at: 
https://www.accessdata.fda.gov/scripts/medwatch/ . 
12.12  Pregnancy  
Pregnancy occurring during a clinical investigation, although not considered a serious adverse event, will be recorded in the eCRF . Study drug will be discontinued among patients confirmed 
to be become pregnant during the study. The pregnancy will be followed until final outcome. Any 
associated AEs or SAEs that occur to the mother or fetus will be recorded in the AE/SAE 
eCRF,.  The pregnancy outcome of a female partner to a male study participant will not be 
followed.   
13 STATISTICAL METHODS AND DATA ANALYSIS  
13.1 General Design Issues  
Planned analyses will be prospectively defined for this study prior to unblinding of data.  
 Primary a nalysis of the PARACOR -19 trial  will be based on the intention to treat (ITT)  principle . 
That is, subject s will be analyzed (and endpoints attributed) according to the treatment strategy 
to which subject s are randomized, regardless of subsequent additional post -randomization 
treatment and medical care. The ITT population will correspond to all randomized subject s. 
Secondary analysis will include per -protocol analysis, which will include randomized patient s 
who remain on assigned study drug and complete the entirety of the study protocol.   Statistical comparisons will be performed using two- sided significance tests. Baseline 
demographic and clinical variables will be summarized for each randomized arm of the study. 
Descriptive summaries of the distribution of continuous variables will be presented in terms of 
percentiles (e.g., median, 25th and 75th percentiles) along with means and standard deviations.  
 
 
 
 
       23
   
 
 
 Categorical variables will be summarized in terms of frequencies and percentages.  
 
In addition, exploratory analyses will be performed to help explain and understand findings 
observed from the planned analyses. Statistical tests with a 2- sided p- value <0.05 will be 
considered statistically significant, unless otherwise stated. Analyses will be performed using 
SAS software (SAS Institute, Inc, Cary, NC).  
13.2 Sample Size Justification and Randomization  
Subjects will be randomized in a 1:1 allocation ratio. We plan to randomize approximately 50 participants  with planned follow -up of 12 weeks. Given the exploratory nature of this early phase 
study, the co- primary endpoints ( relative change in hs -troponin T, relative change in sST2) will 
be assessed separately using a type 1 error of 0.05.   
 
We assume a 25% relative reduction in hs -troponin T compared with placebo at 12 weeks, and 
a 25% relative reduction in sST2 compared with placebo at 12 weeks. A two- sided, two- sample 
t-test with group sample sizes of 25 and 25 achieves at least 80% power to detect a ratio of 0.75 
when the ratio under the null hypothesis is 1.00. The coefficient of variation (CV) on the original scale is assumed to be ≤ 0.36 which is reasonable based on historical data.
18 The significance 
level (alpha) is 0.05.  As the CV decreases, the statistical power increases; however, it the CV 
increases we would need to find a larger ratio to have at least 80% power.  For example, if the 
CV were actually 0.57, then we would have 80.3% power to find a significant ratio of 35%. For all primary and exploratory  biomarker endpoints, values below the lower limit of the assay wi ll 
be imputed with values just below the level of detection, consistent with approaches in prior 
cardiovascular biomarker trials.
18  
13.3 Interim Analyses and Safety Reviews 
It is anticipated that the DSMB will review the accumulating data and schedule ad hoc meetings if SAEs accrue. During such meetings, the DSMB may be provided the following information: 
subject enrollment reports, rates of adherence with the assigned treatment, and description of 
SAEs. The DSMB will review data masked by study group (such as X vs. Y). Due to the size of the trial , no formal interim analysis  of efficacy is planned.  There will be no futility analysis.  
13.4 Analysis of the Co- Primary Endpoint s 
For each serum biomarker, we will calculate the ratio of geometric means at baseline and 12 weeks for the sacubitril/valsartan treatment arm compared with the placebo arm, with 95% confidence intervals.  A two- sample t -test will be used to test for a significant difference using a 
p-value <0.05 for each co- primary endpoint.  A sensitivity analysis will be done using 
generalized linear regression to assess the ratio after adjusting for possible baseline differences.  
 
 
 
 
       24
   
 
 
 13.5 Analysis of Exploratory  Endpoints  
Serum biomarker exploratory  endpoints will be assessed in an identical manner to the co-
primary endpoints.  
 
CMR exploratory  endpoints  will be analyzed as change from baseline using  
linear regression (with treatment, randomization group assignment, and the baseline value as covariates) to determine estimated mean,  the differences compared with placebo, and 95% 
confidence intervals  (CI). Sensitivity analyses will be considered adjusting for possible baseline 
differences.  
14 DATA MANAGEMENT PROCEDURES  
14.1 Overview of Data Management  
The Duke Heart Center Clinical Research Unit  will have primary responsibility for data 
management, including the development of data collection systems, data monitoring processes, and data storage and back -up.   
14.2 Data Security  
Access to databases will be controlled centrally by Duke Heart Center Clinical Research Unit  
through user passwords linked to appropriate privileges. This protects the data from unauthorized changes and inadvertent loss or damage. Database and web servers will be secured by Duke University  firewall and through controlled physical access. All disk drives that 
provide network services, and all user computers, will be protected using virus -scanning 
software.  
14.3 Publication Policy  
Dissemination of preliminary information can adversely affect the objectivity of study data. For 
this reason, investigators will not be allowed to perform subset analyses at any point before the 
conclusion of the study, and any data,  other than safety data, cannot be used for publication or 
reporting outside of this study until the study is completed or discontinued by the DSMB.   
15 STUDY ADMINISTRATION  
15.1 Data and Safety Monitoring Board  
An indepen dent DSMB will be  for this trial . This committee will consist of a group of highly 
experienced individuals with extensive pertinent expertise in HF  and clinical trials . The DSMB 
will advise the investigators  regarding the continuing safety of current subject s and those yet to 
be recruited, as well as the continuing validity and scientific merit of the trial . Safety data, 
summarized at the treatment level, will be assessed approximately every 6 months by the 
 
 
 
 
       25
   
 
 
 DSMB. The safety analyses will be based on the entire ITT population. Safety will be evaluated 
by comparing the occurrence of AEs and changes in laboratory values of the active  treatment  
arm compared to the active control arm . 
15.2 Biomarker Core Laborator y  
Plasma specimens col lected for central laboratory analysis will be sent to the core laboratory for 
measurement of serum  biomarkers. These specimens will be collected at Study Visits  1 and 3, 
processed at the Duke Heart Center Clinical Research Unit  according to the appropriate 
procedures, and shipped to the core laboratory on ice. 
16 REGULATORY ISSUES  
16.1 Ethics and Good Clinical Practice  
This study must be carried out in compliance with the protocol. These procedures are designed 
to ensure adherence to Good Clinical Practice, as described in the following documents:  
1. ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996.  
2. US 21 Code of Federal Regulations dealing with clinical studies (including parts 50 and 56 
concerning informed consent and IRB regulatio ns). 
The investigator s agree to adhere to the instructions and procedures described in the protocol  
and thereby to adhere to the principles of Good Clinical Practice that it conforms to.  
16.2 Institutional Review Board/Independent Ethics Committee  
Before implementing this study, the protocol, the proposed informed consent form and other 
information to subject s must be reviewed by the Duke University IRB. Documentation that the 
protocol and informed consent have been approved by the IRB must be in place before study 
initiation .  Any amendments to the protocol, other than administrative ones, must be approved 
by the IRB . 
16.3 Informed Consent  
The investigator or designee must explain to each subject  (or legally authorized representative) 
the nature of the study, its purpose, the procedures involved, the expected duration, the 
potential risks and benefits involved and any discomfort it may entail. Each subject  must be 
informed that participation in the study is voluntary and that he/she may withdraw from the stu dy 
at any time and that withdrawal of consent will not affect his/her subsequent medical treatment 
or relationship with the treating physician.   The informed consent form (s) must be submitted by 
the investigator for IRB  approval .  
 
 
 
 
       26
   
 
 
 17 APPENDICES  
17.1 Appendix A - Schedule of Assessments 
 
  
 
  Visit number  1 2 3 
Time of Visit  Enrollment/ 
Randomization  Titration Visit  
(Week 1 -2) 12 weeks  
Inclusion/Exclusion criteria  X   
Informed consent  X   
Dispense study medication  X  X  
Demographics, past medical 
history  X    
Vital signs  X X X 
Concurrent medications and 
doses  X X X 
EQ-5D questionnaire  X  X 
Residual COVID Symptoms  X  X 
Urine pregnancy test1 X X X 
Local laboratories  X2 X3 X3 
Serum biomarkers  X4  X4 
Cardiac MRI (30 patients, 
sub-study patients only)  X  X 
Vital status    X 
Adverse events, including 
hospitalizations   X X 
Study medication 
adherence   X X 
1 For women of childbearing potential  
2 hs-TnT, basic metabolic panel (including serum creatinine and serum potassium)  
3 Basic metabolic panel (including renal function and serum potassium)  
4 hs-TnT, sST2, hs -CRP, PINP, Galectin -3, NT -proBNP, GDF -15, IL -6, CITP  
 
 
 
 
       27
   
 
 
 18 REFERENCES   
1. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, 
Escher F, Vasa -Nicotera M, Zeiher AM, Vehreschild M and Nagel E. Outcomes of Cardiovascular 
Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 
(COVID -19). JAMA Cardiol . 2020.  
2. Lindner D, Fitzek A, Brauninger H, Aleshcheva G, Edler C, Meissner K, Scherschel K, 
Kirchhof P, Escher F, Schultheiss HP, Blankenberg S, Puschel K and Westermann D. Association 
of Cardiac Infection With SARS -CoV-2 in Confirmed COVID -19 Autopsy Cases. JAMA Cardiol . 
2020.  
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, 
Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R , Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma 
Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM and Feng Z. Early 
Transmission Dynamics in Wuhan, China, of Novel Coronavirus -Infected Pneumonia. N Engl J 
Med. 2020;382:1199- 1207.  
4. Yancy CW and Fonarow GC. Coronavirus Disease 2019 (COVID -19) and the Heart -Is Heart 
Failure the Next Chapter? JAMA Cardiol . 2020.  
5. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA and Solomon SD. Renin -
Angiotensin -Aldost erone System Inhibitors in Patients with Covid- 19. N Engl J Med . 2020.  
6. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, 
Zannad F and Solomon SD. The role of angiotensin receptor -neprilysin inhibitors in cardiovascular 
disease -existing evidence, knowledge gaps, and future directions. Eur J Heart Fail . 2018;20:963 -
972. 
7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, 
Solomon SD, Swedberg K, Zile MR, Investigators P -H and Committees. Angiotensin -neprilysin 
inhibition versus enalapril in heart failure. N Engl J Med . 2014;371:993 -1004.  
8. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer 
M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ,  Zannad F, Zile MR, Desai 
AS, Claggett B, Jhund PS, Boytsov SA, Comin -Colet J, Cleland J, Dungen HD, Goncalvesova E, 
Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, Investigators P -H and Committees. Angiotensin -Neprilysin Inhibition in 
Heart Failure with Preserved Ejection Fraction. N Engl J Med . 2019;381:1609 -1620.  
9. Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, Zannad F, 
Lam CSP, Janssens S, Jhund PS, Kober L,  Rouleau J, Shah SJ, Chopra VK, Shi VC, Lefkowitz 
MP, Prescott MF, Pfeffer MA, McMurray JJV and Solomon SD. Effects of Sacubitril/Valsartan on N-Terminal Pro -B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. 
JACC Heart Fail . 2020.  
10. Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill 
N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ and Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. 
Circulation . 2018;138:1505 -1514.  
11. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, 
Braunwald E and Investigators P -H. Angiotensin -Neprilysin Inhibition in Acute Decompensated 
Heart Failure. N Engl J Med . 2019;380:539- 548. 
12. Acanfora D, Ciccone MM, Scicchitano P, Acanfora C and Casucci G. Neprilysin inhibitor -
angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS -
CoV-2 patients. Eur Heart J Cardiovasc Pharmacother . 2020;6:135 -136. 
 
 
 
 
       28
   
 
 
 13. Zhang H, Liu G, Zhou W, Zhang W, Wang K and Zhang J. Neprilysin Inhibitor -Angiotensin II 
Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque 
Formation and Inhibits Inflammation in Apolipop rotein E - Deficient Mice. Sci Rep . 2019;9:6509.  
14. Acanfora D, Scicchitano P, Acanfora C, Maestri R, Goglia F, Incalzi RA, Bortone AS, 
Ciccone MM, Uguccioni M and Casucci G. Early Initiation of Sacubitril/Valsartan in Patients with 
Chronic Heart Failure A fter Acute Decompensation: A Case Series Analysis. Clin Drug Investig . 
2020.  
15. Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, 
Zannad F, Chiang LM, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJV, Solomon SD and Zile MR. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matr ix Regulation in 
Patients With HFpEF. J Am Coll Cardiol . 2020;76:503 -514. 
16. Administration USFaD. Entresto US Prescribing Information. 2021;2021.  
17. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, Drazner MH, Filippatos 
GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson 
PN, Stevenson LW and Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 
ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology /American Heart Association Task Force on Clinical Practice Guidelines and the Heart 
Failure Society of America. J Am Coll Cardiol . 2017;70:776 -803. 
18. Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, 
Rocha R and Braunwald E.  Cardiovascular biomarkers in patients with acute decompensated 
heart failure randomized to sacubitril -valsartan or enalapril in the PIONEER -HF trial. Eur Heart J . 
2019;40:3345 -3352.  
 